{"id":745274,"date":"2015-01-13T08:00:00","date_gmt":"2015-01-13T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/"},"modified":"2025-11-07T01:25:23","modified_gmt":"2025-11-07T06:25:23","slug":"lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/","title":{"rendered":"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Combinations of KEYTRUDA\u00ae (pembrolizumab) with Alimta\u00ae (pemetrexed),        Cyramza\u00ae (ramucirumab), or necitumumab to be explored     <\/p>\n<\/p>\n<p>KENILWORTH, N.J. &amp; INDIANAPOLIS&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly<br \/>\n      and Company (NYSE:LLY) announced today an oncology clinical trial<br \/>\n      collaboration to evaluate the safety, tolerability and efficacy of<br \/>\n      KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination<br \/>\n      with Lilly compounds in multiple clinical trials:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Merck will conduct a Phase 2 study examining the combination of<br \/>\n        pembrolizumab with pemetrexed in first-line non-squamous, non-small<br \/>\n        cell lung cancer (NSCLC). This study is currently enrolling.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Lilly will conduct a multiple-arm Phase 1\/2 study examining the<br \/>\n        combination of ramucirumab with pembrolizumab in multiple tumors. This<br \/>\n        study is anticipated to begin in 2015.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Lilly will conduct a Phase 1\/2 study examining the combination of<br \/>\n        necitumumab with pembrolizumab in NSCLC. This study is anticipated to<br \/>\n        begin in 2015.\n      <\/li>\n<\/ul>\n<p>\n      The agreement is between Lilly and Merck, through a subsidiary.<br \/>\n      Additional details of the collaboration were not disclosed.\n    <\/p>\n<p>\n      \u201cCancer is not one disease but rather more than 200 diseases, all of<br \/>\n      which have different causes and treatments,\u201d said Richard Gaynor, M.D.,<br \/>\n      senior vice president, product development and medical affairs, Lilly<br \/>\n      Oncology. \u201cTherefore research into combinations of immune-based<br \/>\n      therapies with other agents that could address these different tumor<br \/>\n      types is important. This collaboration between Lilly and Merck<br \/>\n      represents each company\u2019s strong commitment to patients fighting these<br \/>\n      devastating diseases.\u201d\n    <\/p>\n<p>\n      \u201cOur understanding of the immune system\u2019s role and its impact in the<br \/>\n      treatment of cancer continues to grow,\u201d said Eric Rubin, M.D., vice<br \/>\n      president, global clinical development, oncology, Merck Research<br \/>\n      Laboratories. \u201cCollaborations such as this one are important in<br \/>\n      advancing the investigation of novel immuno-oncology combinations in<br \/>\n      different cancers, and to achieving our shared goal of bringing<br \/>\n      meaningful benefits to patients facing cancer.&#8221;\n    <\/p>\n<p>\n      <b>About KEYTRUDA\u00ae (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>About ALIMTA\u00ae (pemetrexed)<\/b>\n    <\/p>\n<p>\n      In 2004, ALIMTA received consecutive approvals: it was the first agent<br \/>\n      to be approved in combination with cisplatin as a treatment for patients<br \/>\n      with malignant pleural mesothelioma, whose disease is unresectable or<br \/>\n      who are otherwise not candidates for curative surgery, and then as a<br \/>\n      single agent for the second-line treatment of patients with locally<br \/>\n      advanced or metastatic NSCLC after prior chemotherapy treatment.\n    <\/p>\n<p>\n      In 2008, ALIMTA, in combination with cisplatin, was approved as a<br \/>\n      first-line treatment for locally advanced or metastatic NSCLC for<br \/>\n      patients with nonsquamous histology. At the time of the first-line<br \/>\n      approval, the FDA also approved a change to the second-line indication.<br \/>\n      ALIMTA is now indicated as a single agent for the treatment of patients<br \/>\n      with locally advanced or metastatic, nonsquamous NSCLC after prior<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In 2009, ALIMTA was approved as a maintenance therapy for locally<br \/>\n      advanced or metastatic NSCLC, specifically for patients with a<br \/>\n      nonsquamous histology whose disease has not progressed after four cycles<br \/>\n      of platinum-based first-line chemotherapy.\n    <\/p>\n<p>\n      In 2012, ALIMTA was approved by the FDA as a continuation maintenance<br \/>\n      therapy for locally-advanced or metastatic NSCLC, following first-line<br \/>\n      therapy with ALIMTA plus cisplatin in patients with a nonsquamous<br \/>\n      histology.\n    <\/p>\n<p>\n      ALIMTA is not indicated for treatment of patients with squamous cell<br \/>\n      NSCLC. Myelosuppression is usually the dose-limiting toxicity with<br \/>\n      ALIMTA therapy.\n    <\/p>\n<p>\n      <b>About CYRAMZA\u00ae&nbsp;(ramucirumab)<\/b>\n    <\/p>\n<p>\n      CYRAMZA as a single agent, or in combination with paclitaxel (a type of<br \/>\n      chemotherapy), is approved for the treatment of people with advanced or<br \/>\n      metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma<br \/>\n      whose cancer has progressed on or after prior fluoropyrimidine- or<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      CYRAMZA is an antiangiogenic therapy. It is a vascular endothelial<br \/>\n      growth factor (VEGF) Receptor 2 antagonist that specifically binds and<br \/>\n      blocks activation of VEGF Receptor 2, by blocking the binding of VEGF<br \/>\n      receptor ligands VEGF-A, VEGF-C, and VEGF-D. CYRAMZA inhibited<br \/>\n      angiogenesis in an&nbsp;in vivo&nbsp;animal model.\n    <\/p>\n<p>\n      <b>About Necitumumab<\/b>\n    <\/p>\n<p>\n      Necitumumab is an investigational recombinant human IgG1 monoclonal<br \/>\n      antibody that is designed to block the ligand binding site of the human<br \/>\n      epidermal growth factor receptor 1 (EGFR). Activation of EGFR has been<br \/>\n      correlated with malignant progression, induction of angiogenesis and<br \/>\n      inhibition of apoptosis or cell death.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Important Safety Information for ALIMTA\u00ae (pemetrexed for injection)<\/b>\n    <\/p>\n<p>\n      <b>Myelosuppression is usually the dose-limiting toxicity with ALIMTA<br \/>\n      therapy.<\/b>\n    <\/p>\n<p>\n      <b>Contraindication<\/b>\n    <\/p>\n<p>\n      ALIMTA is contraindicated in patients who have a history of severe<br \/>\n      hypersensitivity reaction to pemetrexed.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      Prior to treatment with ALIMTA, patients must be instructed to initiate<br \/>\n      supplementation with oral folic acid. Additionally, intramuscular<br \/>\n      injections of vitamin B<sub>12<\/sub> are also required prior to ALIMTA<br \/>\n      treatment. Folic acid and vitamin B<sub>12<\/sub> supplementation should<br \/>\n      be continued throughout treatment as they may reduce the severity of<br \/>\n      treatment-related hematologic and GI toxicities. Dexamethasone or its<br \/>\n      equivalent should be administered the day before, the day of, and the<br \/>\n      day after ALIMTA treatment.\n    <\/p>\n<p>\n      ALIMTA can suppress bone marrow function, as manifested by neutropenia,<br \/>\n      thrombocytopenia, and anemia (or pancytopenia). Reduce doses for<br \/>\n      subsequent cycles based on hematologic and nonhematologic toxicities.\n    <\/p>\n<p>\n      ALIMTA should not be administered to patients with a creatinine<br \/>\n      clearance &lt;45 mL\/min. One patient with severe renal impairment<br \/>\n      (creatinine clearance 19 mL\/min) who did not receive folic acid and<br \/>\n      vitamin B<sub>12<\/sub> died of drug-related toxicity following<br \/>\n      administration of ALIMTA alone.\n    <\/p>\n<p>\n      Caution should be used when administering NSAIDs concurrently with<br \/>\n      ALIMTA to patients with mild to moderate renal insufficiency (creatinine<br \/>\n      clearance from 45 to 79 mL\/min). Patients with mild to moderate renal<br \/>\n      insufficiency should avoid taking NSAIDs with short elimination<br \/>\n      half-lives for a period of 2 days before, the day of, and 2 days<br \/>\n      following administration of ALIMTA. In the absence of data regarding<br \/>\n      potential interaction between ALIMTA and NSAIDs with longer half-lives,<br \/>\n      all patients taking these NSAIDs should interrupt dosing for at least 5<br \/>\n      days before, the day of, and 2 days following ALIMTA administration. If<br \/>\n      concomitant administration of NSAIDs is necessary, patients should be<br \/>\n      monitored closely for toxicity, especially myelosuppression, renal, and<br \/>\n      gastrointestinal toxicity. No dose adjustment of ALIMTA is needed with<br \/>\n      concomitant NSAIDs in patients with normal renal function.\n    <\/p>\n<p>\n      Do not initiate a cycle of treatment in patients unless the ANC is \u22651500<br \/>\n      cells\/mm<sup>3<\/sup>, the platelet count is \u2265100,000 cells\/mm<sup>3<\/sup>,<br \/>\n      and creatinine clearance is \u226545 mL\/min.\n    <\/p>\n<p>\n      Pregnancy Category D\u2014ALIMTA may cause fetal harm when administered to a<br \/>\n      pregnant woman. Women should be apprised of the potential hazard to the<br \/>\n      fetus and should be advised to use effective contraceptive measures to<br \/>\n      prevent pregnancy during treatment with ALIMTA.\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      See Warnings and Precautions for specific information regarding NSAID<br \/>\n      administration in patients with renal insufficiency.\n    <\/p>\n<p>\n      Concomitant administration of nephrotoxic drugs or substances that are<br \/>\n      tubularly secreted could result in delayed clearance of ALIMTA.\n    <\/p>\n<p>\n      <b>Use in Specific Patient Populations<\/b>\n    <\/p>\n<p>\n      It is recommended that nursing be discontinued if the mother is being<br \/>\n      treated with ALIMTA or discontinue the drug, taking into account the<br \/>\n      importance of the drug for the mother.\n    <\/p>\n<p>\n      Efficacy of ALIMTA in pediatric patients has not been demonstrated. The<br \/>\n      most common toxicities reported in the studied pediatric patients were<br \/>\n      hematological (leukopenia, neutropenia\/granulocytopenia, anemia,<br \/>\n      thrombocytopenia, and lymphopenia), liver function abnormalities<br \/>\n      (increased ALT\/AST), fatigue, and nausea.\n    <\/p>\n<p>\n      <b>Dosage and Administration Guidelines<\/b>\n    <\/p>\n<p>\n      Complete blood cell counts, including platelet counts and periodic<br \/>\n      chemistry tests, which include renal and hepatic function tests, should<br \/>\n      be performed on all patients receiving ALIMTA.\n    <\/p>\n<p>\n      Dose adjustments at the start of a subsequent cycle should be based on<br \/>\n      nadir hematologic counts or maximum nonhematologic toxicity from the<br \/>\n      preceding cycle of therapy. Modify or suspend therapy according to the<br \/>\n      Dosage Reduction Guidelines in the full Prescribing Information.\n    <\/p>\n<p>\n      <b>Abbreviated Adverse Reactions (% incidence) \u2013 1st-line advanced<br \/>\n      nonsquamous non-small cell lung cancer (NS NSCLC)<\/b>\n    <\/p>\n<p>\n      The most severe adverse reactions (grades 3-4) with ALIMTA in<br \/>\n      combination with cisplatin versus gemcitabine in combination with<br \/>\n      cisplatin, respectively, for the 1st-line treatment of patients with<br \/>\n      advanced nonsquamous non-small cell lung cancer (NSCLC) were neutropenia<br \/>\n      (15% vs 27%); leukopenia (5% vs 8%); thrombocytopenia (4% vs 13%);<br \/>\n      anemia (6% vs 10%); fatigue (7% vs 5%); nausea (7% vs 4%); vomiting (6%<br \/>\n      vs 6%); anorexia (2% vs 1%); creatinine elevation (1% vs 1%); and<br \/>\n      diarrhea (1% vs 2%).\n    <\/p>\n<p>\n      Common adverse reactions (all grades) with ALIMTA in combination with<br \/>\n      cisplatin versus gemcitabine in combination with cisplatin,<br \/>\n      respectively, were nausea (56% vs 53%); fatigue (43% vs 45%); vomiting<br \/>\n      (40% vs 36%); anemia (33% vs 46%); neutropenia (29% vs 38%); anorexia<br \/>\n      (27% vs 24%); constipation (21% vs 20%); leukopenia (18% vs 21%);<br \/>\n      stomatitis\/pharyngitis (14% vs 12%); alopecia (12% vs 21%); diarrhea<br \/>\n      (12% vs 13%); thrombocytopenia (10% vs 27%); neuropathy\/sensory (9% vs<br \/>\n      12%); taste disturbance (8% vs 9%); rash\/desquamation (7% vs 8%);<br \/>\n      dyspepsia\/heartburn (5% vs 6%); and creatinine elevation (10% vs 7%).\n    <\/p>\n<p>\n      <b>Abbreviated Adverse Reactions (% incidence) \u2013 Maintenance in advanced<br \/>\n      NS NSCLC following non-ALIMTA containing, platinum-based induction<br \/>\n      therapy<\/b>\n    <\/p>\n<p>\n      The most severe adverse reactions (grades 3-4) with ALIMTA as a single<br \/>\n      agent versus placebo, respectively, for the maintenance treatment of<br \/>\n      patients with locally advanced nonsquamous non-small cell lung cancer<br \/>\n      (NS NSCLC) following non-ALIMTA containing platinum-based induction<br \/>\n      therapy were anemia (3% vs 1%); neutropenia (3% vs 0%); leukopenia (2%<br \/>\n      vs 1%); fatigue (5% vs 1%); nausea (1% vs 1%); anorexia (2% vs 0%);<br \/>\n      mucositis\/stomatitis (1% vs 0%); diarrhea (1% vs 0%); infection (2% vs<br \/>\n      0%); and neuropathy-sensory (1% vs 0%).\n    <\/p>\n<p>\n      Common adverse reactions (all grades) with ALIMTA as a single agent<br \/>\n      versus placebo, respectively, after non-ALIMTA containing platinum-based<br \/>\n      induction therapy were anemia (15% vs 6%); neutropenia (6% vs 0%);<br \/>\n      leukopenia (6% vs 1%); increased ALT (10% vs 4%); increased AST (8% vs<br \/>\n      4%); fatigue (25% vs 11%); nausea (19% vs 6%); anorexia (19% vs 5%);<br \/>\n      vomiting (9% vs 1%); mucositis\/stomatitis (7% vs 2%); diarrhea (5% vs<br \/>\n      3%); infection (5% vs 2%); neuropathy-sensory (9% vs 4%); and<br \/>\n      rash\/desquamation (10% vs 3%).\n    <\/p>\n<p>\n      <b>Abbreviated Adverse Reactions (% incidence) \u2013 Maintenance in advanced<br \/>\n      NS NSCLC following ALIMTA plus cisplatin induction therapy<\/b>\n    <\/p>\n<p>\n      The most severe adverse reactions (grades 3-4) with ALIMTA as a single<br \/>\n      agent versus placebo, respectively, for the maintenance treatment of<br \/>\n      patients with locally advanced nonsquamous non-small cell lung cancer<br \/>\n      (NS NSCLC) following ALIMTA plus cisplatin induction therapy were anemia<br \/>\n      (4.8% vs 0.6%); neutropenia (3.9% vs 0%); and fatigue (4.5% vs 0.6%).\n    <\/p>\n<p>\n      Common adverse reactions (all grades) with ALIMTA as a single agent<br \/>\n      versus placebo, respectively, following ALIMTA plus cisplatin induction<br \/>\n      therapy were anemia (15% vs 4.8%); neutropenia (9% vs 0.6%); fatigue<br \/>\n      (18% vs 11%); nausea (12% vs 2.4%); vomiting (6% vs 1.8%);<br \/>\n      mucositis\/stomatitis (5% vs 2.4%); and edema (5% vs 3.6%).\n    <\/p>\n<p>\n      <b>Abbreviated Adverse Reactions (% incidence) \u2013 2nd-line advanced NS<br \/>\n      NSCLC<\/b>\n    <\/p>\n<p>\n      The most severe adverse reactions (grades 3-4) with ALIMTA as a single<br \/>\n      agent versus docetaxel, respectively, for the 2nd-line treatment of<br \/>\n      patients with advanced non-small cell lung cancer (NSCLC) were<br \/>\n      neutropenia (5% vs 40%); leukopenia (4% vs 27%); thrombocytopenia (2% vs<br \/>\n      0%); anemia (4% vs 4%); fatigue (5% vs 5%); nausea (3% vs 2%); anorexia<br \/>\n      (2% vs 3%); vomiting (2% vs 1%); increased ALT (2% vs 0%); increased AST<br \/>\n      (1% vs 0%); and stomatitis\/pharyngitis (1% vs 1%).\n    <\/p>\n<p>\n      Common adverse reactions (all grades) with ALIMTA as a single agent<br \/>\n      versus docetaxel, respectively, were fatigue (34% vs 36%); nausea (31%<br \/>\n      vs 17%); anorexia (22% vs 24%); anemia (19% vs 22%); vomiting (16% vs<br \/>\n      12%); stomatitis\/pharyngitis (15% vs 17%); rash (14% vs 6%); diarrhea<br \/>\n      (13% vs 24%); leukopenia (12% vs 34%); thrombocytopenia (8% vs 1%);<br \/>\n      increased ALT (8% vs 1%); increased AST (7% vs 1%); constipation (6% vs<br \/>\n      4%); fever (8% vs 8%); pruritus (7% vs 2%); alopecia (6% vs 38%); and<br \/>\n      neutropenia (11% vs 45%).\n    <\/p>\n<p>\n      <b>For safety and dosing guidelines, see complete Warnings and<br \/>\n      Precautions, Adverse Reactions, and Dosage and Administration sections<br \/>\n      in the accompanying full Prescribing Information.<\/b>\n    <\/p>\n<p>\n      PM_HCP_ISI_NSCLCall_17OCT2012\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION FOR CYRAMZA<\/b>\n    <\/p>\n<p>\n      <b>WARNING: HEMORRHAGE<\/b><br \/><b>CYRAMZA increased the risk of<br \/>\n      hemorrhage, including severe and sometimes fatal hemorrhagic events.<br \/>\n      Permanently discontinue CYRAMZA in patients who experience severe<br \/>\n      bleeding.<\/b>\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Hemorrhage<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        CYRAMZA increased the risk of hemorrhage and gastrointestinal<br \/>\n        hemorrhage including severe and sometimes fatal hemorrhagic events. In<br \/>\n        Study 1, which evaluated CYRAMZA as a single agent in advanced gastric<br \/>\n        cancer, the incidence of severe bleeding was 3.4% for CYRAMZA and 2.6%<br \/>\n        for placebo. In Study 2, which evaluated CYRAMZA plus paclitaxel in<br \/>\n        advanced gastric cancer, the incidence of severe bleeding was 4.3% for<br \/>\n        CYRAMZA plus paclitaxel and 2.4% for placebo plus paclitaxel. Patients<br \/>\n        with gastric cancer receiving nonsteroidal anti-inflammatory drugs<br \/>\n        (NSAIDs) were excluded from enrollment in Studies 1 and 2; therefore,<br \/>\n        the risk of gastric hemorrhage in CYRAMZA-treated patients with<br \/>\n        gastric tumors receiving NSAIDs is unknown. In Study 3, which<br \/>\n        evaluated CYRAMZA plus docetaxel in metastatic non-small cell lung<br \/>\n        cancer (NSCLC), the incidence of severe bleeding was 2.4% for CYRAMZA<br \/>\n        plus docetaxel and 2.3% for placebo plus docetaxel. Patients with<br \/>\n        NSCLC receiving therapeutic anticoagulation or chronic therapy with<br \/>\n        NSAIDs or other antiplatelet therapy other than once-daily aspirin or<br \/>\n        with radiographic evidence of major airway or blood vessel invasion or<br \/>\n        intratumor cavitation were excluded from Study 3; therefore, the risk<br \/>\n        of pulmonary hemorrhage in these groups of patients is unknown.<br \/>\n        Permanently discontinue CYRAMZA in patients who experience severe<br \/>\n        bleeding.\n      <\/li>\n<\/ul>\n<p>\n      <b>Arterial Thromboembolic Events<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Serious, sometimes fatal, arterial thromboembolic events (ATEs)<br \/>\n        including myocardial infarction, cardiac arrest, cerebrovascular<br \/>\n        accident, and cerebral ischemia occurred in clinical trials including<br \/>\n        1.7% of 236 patients who received CYRAMZA as a single agent for<br \/>\n        gastric cancer in Study 1. Permanently discontinue CYRAMZA in patients<br \/>\n        who experience a severe ATE.\n      <\/li>\n<\/ul>\n<p>\n      <b>Hypertension<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        An increased incidence of severe hypertension occurred in patients<br \/>\n        receiving CYRAMZA as a single agent (8%) as compared to placebo (3%),<br \/>\n        in patients receiving CYRAMZA plus paclitaxel (15%) as compared to<br \/>\n        placebo plus paclitaxel (3%), and in patients receiving CYRAMZA plus<br \/>\n        docetaxel (6%) as compared to placebo plus docetaxel (2%). Control<br \/>\n        hypertension prior to initiating treatment with CYRAMZA. Monitor blood<br \/>\n        pressure every 2 weeks or more frequently as indicated during<br \/>\n        treatment. Temporarily suspend CYRAMZA for severe hypertension until<br \/>\n        medically controlled. Permanently discontinue CYRAMZA if medically<br \/>\n        significant hypertension cannot be controlled with antihypertensive<br \/>\n        therapy or in patients with hypertensive crisis or hypertensive<br \/>\n        encephalopathy.\n      <\/li>\n<\/ul>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Prior to the institution of premedication recommendations across<br \/>\n        clinical trials of CYRAMZA, infusion-related reactions (IRRs) occurred<br \/>\n        in 6 out of 37 patients (16%), including 2 severe events. The majority<br \/>\n        of IRRs across trials occurred during or following a first or second<br \/>\n        CYRAMZA infusion. Symptoms of IRRs included rigors\/tremors, back<br \/>\n        pain\/spasms, chest pain and\/or tightness, chills, flushing, dyspnea,<br \/>\n        wheezing, hypoxia, and paresthesia. In severe cases, symptoms included<br \/>\n        bronchospasm, supraventricular tachycardia, and hypotension. Monitor<br \/>\n        patients during the infusion for signs and symptoms of IRRs in a<br \/>\n        setting with available resuscitation equipment. Immediately and<br \/>\n        permanently discontinue CYRAMZA for Grade 3 or 4 IRRs.\n      <\/li>\n<\/ul>\n<p>\n      <b>Gastrointestinal Perforations<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        CYRAMZA is an antiangiogenic therapy that can increase the risk of<br \/>\n        gastrointestinal perforation, a potentially fatal event. Four of 570<br \/>\n        patients (0.7%) who received CYRAMZA as a single agent in advanced<br \/>\n        gastric cancer clinical trials experienced gastrointestinal<br \/>\n        perforation. In Study 2, the incidence of gastrointestinal perforation<br \/>\n        was 1.2% for CYRAMZA plus paclitaxel as compared to 0.3% for placebo<br \/>\n        plus paclitaxel. In Study 3, the incidence of gastrointestinal<br \/>\n        perforation was 1% for CYRAMZA plus docetaxel as compared to 0.3% for<br \/>\n        placebo plus docetaxel. Permanently discontinue CYRAMZA in patients<br \/>\n        who experience a gastrointestinal perforation.\n      <\/li>\n<\/ul>\n<p>\n      <b>Impaired Wound Healing<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        CYRAMZA has not been studied in patients with serious or nonhealing<br \/>\n        wounds. CYRAMZA is an antiangiogenic therapy with the potential to<br \/>\n        adversely affect wound healing. Withhold CYRAMZA prior to surgery.<br \/>\n        Resume CYRAMZA following the surgical intervention based on clinical<br \/>\n        judgment of adequate wound healing. If a patient develops wound<br \/>\n        healing complications during therapy, discontinue CYRAMZA until the<br \/>\n        wound is fully healed.\n      <\/li>\n<\/ul>\n<p>\n      <b>Clinical Deterioration in Child-Pugh B or C Cirrhosis<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Clinical deterioration, manifested by new onset or worsening<br \/>\n        encephalopathy, ascites, or hepatorenal syndrome, was reported in<br \/>\n        patients with Child-Pugh B or C cirrhosis who received single-agent<br \/>\n        CYRAMZA. Use CYRAMZA in patients with Child-Pugh B or C cirrhosis only<br \/>\n        if the potential benefits of treatment are judged to outweigh the<br \/>\n        risks of clinical deterioration.\n      <\/li>\n<\/ul>\n<p>\n      <b>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        RPLS has been reported at a rate of &lt;0.1% in clinical studies with<br \/>\n        CYRAMZA. Confirm the diagnosis of RPLS with MRI and discontinue<br \/>\n        CYRAMZA in patients who develop RPLS. Symptoms may resolve or improve<br \/>\n        within days, although some patients with RPLS can experience ongoing<br \/>\n        neurologic sequelae or death.\n      <\/li>\n<\/ul>\n<p>\n      <b>Most Common Adverse Reactions\u2014Single Agent<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The most commonly reported adverse reactions (all grades; Grade 3\/4)<br \/>\n        occurring in \u22655% of patients receiving CYRAMZA and \u22652% higher than<br \/>\n        placebo in Study 1 were hypertension (16% vs 8%; 8% vs 3%), diarrhea<br \/>\n        (14% vs 9%; 1% vs 2%), headache (9% vs 3%; 0% vs 0%), and hyponatremia<br \/>\n        (6% vs 2%; 3% vs 1%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The most common serious adverse events with CYRAMZA in Study 1 were<br \/>\n        anemia (3.8%) and intestinal obstruction (2.1%). Red blood cell<br \/>\n        transfusions were given to 11% of CYRAMZA-treated patients vs 8.7% of<br \/>\n        patients who received placebo.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Clinically relevant adverse reactions reported in \u22651% and &lt;5% of<br \/>\n        CYRAMZA-treated patients vs placebo in Study 1 were: neutropenia (4.7%<br \/>\n        vs 0.9%), epistaxis (4.7% vs 0.9%), rash (4.2% vs 1.7%), intestinal<br \/>\n        obstruction (2.1% vs 0%), and arterial thromboembolic events (1.7% vs<br \/>\n        0%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical trials of CYRAMZA administered as a single agent,<br \/>\n        clinically relevant adverse reactions (including Grade \u22653) reported in<br \/>\n        CYRAMZA-treated patients included proteinuria, gastrointestinal<br \/>\n        perforation, and infusion-related reactions. In Study 1, according to<br \/>\n        laboratory assessment, 8% of CYRAMZA-treated patients developed<br \/>\n        proteinuria vs 3% of placebo-treated patients. Two patients<br \/>\n        discontinued CYRAMZA due to proteinuria. The rate of gastrointestinal<br \/>\n        perforation in Study 1 was 0.8% and the rate of infusion-related<br \/>\n        reactions was 0.4%.\n      <\/li>\n<\/ul>\n<p>\n      <b>Most Common Adverse Reactions\u2014Combination With Paclitaxel<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The most commonly reported adverse reactions (all grades; Grade 3\/4)<br \/>\n        occurring in \u22655% of patients receiving CYRAMZA plus paclitaxel and \u22652%<br \/>\n        higher than placebo plus paclitaxel in Study 2 were fatigue\/asthenia<br \/>\n        (57% vs 44%; 12% vs 6%), neutropenia (54% vs 31%; 41% vs 19%),<br \/>\n        diarrhea (32% vs 23%; 4% vs 2%), epistaxis (31% vs 7%; 0% vs 0%),<br \/>\n        hypertension (25% vs 6%; 15% vs 3%), peripheral edema (25% vs 14%; 2%<br \/>\n        vs 1%), stomatitis (20% vs 7%; 1% vs 1%), proteinuria (17% vs 6%; 1%<br \/>\n        vs 0%), thrombocytopenia (13% vs 6%; 2% vs 2%), hypoalbuminemia (11%<br \/>\n        vs 5%; 1% vs 1%), and gastrointestinal hemorrhage events (10% vs 6%;<br \/>\n        4% vs 2%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The most common serious adverse events with CYRAMZA plus paclitaxel in<br \/>\n        Study 2 were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of<br \/>\n        patients treated with CYRAMZA plus paclitaxel received granulocyte<br \/>\n        colony-stimulating factors.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Adverse reactions resulting in discontinuation of any component of the<br \/>\n        CYRAMZA plus paclitaxel combination in 2% or more patients in Study 2<br \/>\n        were neutropenia (4%) and thrombocytopenia (3%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Clinically relevant adverse reactions reported in \u22651% and &lt;5% of the<br \/>\n        CYRAMZA plus paclitaxel-treated patients in Study 2 were sepsis (3.1%<br \/>\n        for CYRAMZA plus paclitaxel vs 1.8% for placebo plus paclitaxel) and<br \/>\n        gastrointestinal perforations (1.2% for CYRAMZA plus paclitaxel vs<br \/>\n        0.3% for placebo plus paclitaxel).\n      <\/li>\n<\/ul>\n<p>\n      <b>Most Common Adverse Reactions\u2014Combination With Docetaxel<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The most commonly reported adverse reactions (all grades; Grade 3\/4)<br \/>\n        occurring in \u22655% of patients receiving CYRAMZA plus docetaxel and \u22652%<br \/>\n        higher than placebo plus docetaxel in Study 3 were neutropenia (55% vs<br \/>\n        46%; 49% vs 40%), fatigue\/asthenia (55% vs 50%; 14% vs 11%),<br \/>\n        stomatitis\/mucosal inflammation (37% vs 19%; 7% vs 2%), epistaxis (19%<br \/>\n        vs 7%; &lt;1% vs &lt;1%), febrile neutropenia (16% vs 10%; 16% vs 10%),<br \/>\n        peripheral edema (16% vs 9%; 0% vs &lt;1%), thrombocytopenia (13% vs 5%;<br \/>\n        3% vs &lt;1%), lacrimation increased (13% vs 5%; &lt;1% vs 0%), and<i> <\/i>hypertension<br \/>\n        (11% vs 5%; 6% vs 2%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The most common serious adverse events with CYRAMZA plus docetaxel in<br \/>\n        Study 3 were febrile neutropenia (14%), pneumonia (6%), and<br \/>\n        neutropenia (5%). The use of granulocyte colony-stimulating factors<br \/>\n        was 42% in CYRAMZA plus docetaxel-treated patients versus 37% in<br \/>\n        patients who received placebo plus docetaxel.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Treatment discontinuation due to adverse reactions occurred more<br \/>\n        frequently in CYRAMZA plus docetaxel-treated patients (9%) than in<br \/>\n        placebo plus docetaxel-treated patients (5%). The most common adverse<br \/>\n        events leading to treatment discontinuation of CYRAMZA in Study 3 were<br \/>\n        infusion-related reaction (0.5%) and epistaxis (0.3%).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Clinically relevant adverse reactions reported in \u22651% and &lt;5% of<br \/>\n        CYRAMZA plus docetaxel-treated patients in Study 3 were hyponatremia<br \/>\n        (4.8% CYRAMZA plus docetaxel versus 2.4% for placebo plus docetaxel)<br \/>\n        and proteinuria (3.3% CYRAMZA plus docetaxel versus 0.8% placebo plus<br \/>\n        docetaxel).\n      <\/li>\n<\/ul>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        No pharmacokinetic (PK) interactions were observed between ramucirumab<br \/>\n        (CYRAMZA) and paclitaxel or between ramucirumab (CYRAMZA) and<br \/>\n        docetaxel.\n      <\/li>\n<\/ul>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Pregnancy Category C: Based on its mechanism of action, CYRAMZA may<br \/>\n        cause fetal harm. Advise females of reproductive potential to avoid<br \/>\n        getting pregnant, including use of adequate contraception, while<br \/>\n        receiving CYRAMZA and for at least 3 months after the last dose of<br \/>\n        CYRAMZA. Animal models link angiogenesis, VEGF and VEGF Receptor 2 to<br \/>\n        critical aspects of female reproduction, embryofetal development, and<br \/>\n        postnatal development. There are no adequate or well-controlled<br \/>\n        studies of ramucirumab in pregnant women. If this drug is used during<br \/>\n        pregnancy, or if the patient becomes pregnant while taking this drug,<br \/>\n        apprise the patient of the potential hazard to a fetus.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Nursing Mothers: It is recommended to discontinue nursing or<br \/>\n        discontinue CYRAMZA due to the potential risks to the nursing infant.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Females of Reproductive Potential: Advise females of reproductive<br \/>\n        potential that CYRAMZA may impair fertility.\n      <\/li>\n<\/ul>\n<p>\n      <b>Please see full <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fpi.lilly.com%2Fus%2Fcyramza-pi.pdf&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=ee0fd2ea55444f2dc9651626277486d4\" rel=\"nofollow\"><b>Prescribing<br \/>\n      Information<\/b><\/a><b> for CYRAMZA, including Boxed Warning for<br \/>\n      hemorrhage.<\/b>\n    <\/p>\n<p>\n      RB-P HCP ISI 16DEC2014\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology and other areas of breakthrough science is our focus to<br \/>\n      potentially bring new hope to people with cancer. For more information<br \/>\n      about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=0c98c6a7d75bd282c1c14efec051050a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=1d8340957aa6da51dcbe71ce586d5b9c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=d700122c99e3b6febe596e752ad0e737\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=34b8e38e1ed92e0d57f8ce042f9d58bd\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=3a228d44a247ce22813f84eca8219b0d\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About Lilly Oncology<\/b>\n    <\/p>\n<p>\n      For more than fifty years, Lilly has been dedicated to delivering<br \/>\n      life-changing medicines and support to people living with cancer and<br \/>\n      those who care for them. Lilly is determined to build on this heritage<br \/>\n      and continue making life better for all those affected by cancer around<br \/>\n      the world. To learn more about Lilly&#8217;s commitment to people with cancer,<br \/>\n      please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lillyoncology.com%2F&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=www.LillyOncology.com&amp;index=7&amp;md5=212ff81e6caf97037b2f725dbfbb5f76\" rel=\"nofollow\">www.LillyOncology.com<\/a>.\n    <\/p>\n<p>\n      <b>About Eli Lilly and Company<\/b>\n    <\/p>\n<p>\n      Lilly is a global healthcare leader that unites caring with discovery to<br \/>\n      make life better for people around the world. We were founded more than<br \/>\n      a century ago by a man committed to creating high-quality medicines that<br \/>\n      meet real needs, and today we remain true to that mission in all our<br \/>\n      work. Across the globe, Lilly employees work to discover and bring<br \/>\n      life-changing medicines to those who need them, improve the<br \/>\n      understanding and management of disease, and give back to communities<br \/>\n      through philanthropy and volunteerism. To learn more about Lilly, please<br \/>\n      visit us at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lilly.com%2F&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=www.lilly.com&amp;index=8&amp;md5=3c5ef136f17aec7673dd6cc9b9291b8a\" rel=\"nofollow\">www.lilly.com<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fnewsroom.lilly.com%2Fsocial-channels&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=newsroom.lilly.com%2Fsocial-channels&amp;index=9&amp;md5=53c7fcfcf97859b2730942afbfddfa1a\" rel=\"nofollow\">newsroom.lilly.com\/social-channels<\/a>.\n    <\/p>\n<p>\n      C-LLY\n    <\/p>\n<p>\n      RB93109 12\/2014 \u00a9 Lilly USA, LLC 2014. ALL RIGHTS RESERVED.<br \/>CYRAMZA<sup>\u00ae<\/sup><br \/>\n      is a registered trademark of Eli Lilly and Company.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=d75465229f8631f627777452ba75d5dc\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Lilly Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      <i>This press release contains \u201cforward-looking statements\u201d (as that<br \/>\n      term is defined in the United States Private Securities Litigation<br \/>\n      Reform Act of 1995) regarding the research collaboration between Merck<br \/>\n      and Lilly.<\/i> <i>This press release reflects Lilly&#8217;s current beliefs.<br \/>\n      However, there are substantial risks and uncertainties in the process of<br \/>\n      drug research, development, and commercialization. Among other risks,<br \/>\n      there can be no guarantee that this investigational combination regimen<br \/>\n      will receive regulatory approval, or, if approved, that it will achieve<br \/>\n      intended benefits or become a commercially successful product. For<br \/>\n      further discussion of these and other risks and uncertainties that could<br \/>\n      cause actual results to differ materially from Lilly&#8217;s expectations,<br \/>\n      please see the company&#8217;s latest Forms 10-K and 10-Q filed with the U.S.<br \/>\n      Securities and Exchange Commission. Except as required by law, Lilly<br \/>\n      undertakes no duty to update forward-looking statements.<\/i>\n    <\/p>\n<p>\n      P-LLY\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150113005234r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20150113005234\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20150113005234\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Investors:<br \/>Justin Holko,        908-740-1879<br \/>or<br \/>Lilly<br \/>Eli Lilly and Company<br \/>Keri        McGrath, 317-277-3768<br \/>Communications Manager<br \/><a href=\"mailto:mcgrath_happeks@lilly.com\">mcgrath_happeks@lilly.com<\/a>     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1\/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1\/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed. \u201cCancer is not one disease but<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-745274","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1\/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1\/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed. \u201cCancer is not one disease but\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"24 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\\\/\",\"name\":\"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-01-13T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1\/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1\/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed. \u201cCancer is not one disease but","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:23+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"24 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/","name":"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-01-13T08:00:00+00:00","dateModified":"2025-11-07T06:25:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lilly-merck-enter-collaboration-agreement-to-research-immuno-oncology-combination-regimens-in-multiple-types-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9fd0a029-9c55-42f7-a327-652a1c4a7efd","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/01\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/01\/1\/Lily_Logo-5B1-5D.jpg","size":"25845","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Lilly-Merck-Enter-Collaboration-Agreement-to-Research-Immuno-Oncology-Combination-Regimens-in-Multiple-Types-of-Cancer-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745274\/revisions"}],"predecessor-version":[{"id":3674693,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745274\/revisions\/3674693"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745274"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}